0001209191-14-077088.txt : 20141219 0001209191-14-077088.hdr.sgml : 20141219 20141219173421 ACCESSION NUMBER: 0001209191-14-077088 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20141217 FILED AS OF DATE: 20141219 DATE AS OF CHANGE: 20141219 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BELLICUM PHARMACEUTICALS, INC CENTRAL INDEX KEY: 0001358403 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 2130 WEST HOLCOMBE BOULEVARD STREET 2: SUITE 850 CITY: HOUSTON STATE: TX ZIP: 77030 BUSINESS PHONE: (832) 384-1100 MAIL ADDRESS: STREET 1: 2130 WEST HOLCOMBE BOULEVARD STREET 2: SUITE 850 CITY: HOUSTON STATE: TX ZIP: 77030 FORMER COMPANY: FORMER CONFORMED NAME: BELLICUM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Remeditex Ventures LLC CENTRAL INDEX KEY: 0001627363 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36783 FILM NUMBER: 141300796 BUSINESS ADDRESS: STREET 1: 2101 CEDAR SPRINGS ROAD, SUITE 601 CITY: DALLAS STATE: TX ZIP: 75201 BUSINESS PHONE: (214) 506-2662 MAIL ADDRESS: STREET 1: 2101 CEDAR SPRINGS ROAD, SUITE 601 CITY: DALLAS STATE: TX ZIP: 75201 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2014-12-17 0 0001358403 BELLICUM PHARMACEUTICALS, INC BLCM 0001627363 Remeditex Ventures LLC 2101 CEDAR SPRINGS ROAD, SUITE 601 DALLAS TX 75201 0 0 1 0 Warrant to Purchase Series C Preferred Stock (right to buy) 6.00 2014-12-17 4 X 0 271055 0.00 D 2014-08-22 2019-08-22 Series C Preferred Stock 271055 0 D Series C Convertible Preferred Stock 2014-12-17 4 X 0 271055 A Common Stock 159444 159444 D Upon the date immediately following the date of the effectiveness of the initial public offering of the Issuer, on or prior to March 31, 2015, the warrants will be terminated if not previously exercised. The Series C Convertible Preferred Stock ("Preferred Stock") are convertible into the Issuer's common stock at a conversion rate of 1 share of common stock for each 1.7 shares of Preferred Stock and have no expiration date. By: /s/ Brett A. Ringle, President 2014-12-19